Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Subcutaneous Goserelin vs Zoladex in Advanced Prostate Cancer
NCT03936218Phase 3Completed
- Sponsor
- Eurofarma
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Eurofarma. Primary endpoint: Pharmacodynamics of test product against reference product at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03936218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936218.